News Related to Xerostomia

Related coverage linked through entity extraction aliases.

Telix Gains FDA Alignment to Advance ProstACT Global Phase 3 Trial in U.S.

Jul 02, 2026

Telix gained FDA alignment to advance ProstACT Global Phase 3 into U.S. Part 2 for TLX591-Tx in mCRPC, with safety data from Part 1 deemed sufficient. The trial will combine the therapy with abiraterone, enzalutamide, or docetaxel, pending IND amendment review.

Advances in Head and Neck Cancer Treatment Focus on Reducing Radiation Toxicity

Feb 14, 2026

New research and precision radiation techniques aim to minimize debilitating side effects of head and neck cancer treatment, including oral mucositis, while maintaining tumor control and improving patient quality of life.